tiprankstipranks
Guardant Health (MX:GH)
:GH
Mexico Market
GH
Guardant Health
RESEARCH TOOLSreports

Guardant Health (GH) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

GH Analyst Ratings

Strong Buy
20Ratings
Strong Buy
20 Buy
0 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Guardant
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GH Stock 12 Month Forecast

Average Price Target

$3,298.81
▲(18.49% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $3,298.81 with a high forecast of $3,636.12 and a low forecast of $2,114.02. The average price target represents a 18.49% change from the last price of $2,784.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"954":"$954","3637":"$3,637","1624.75":"$1,624.8","2295.5":"$2,295.5","2966.25":"$2,966.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3636.11764005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.64K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3298.813703931666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.30K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2114.02188375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[954,1624.75,2295.5,2966.25,3637],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2784,2849.5475107730767,2915.095021546154,2980.6425323192307,3046.190043092308,3111.7375538653846,3177.2850646384613,3242.8325754115385,3308.3800861846153,3373.927596957692,3439.475107730769,3505.022618503846,3570.5701292769227,{"y":3636.11764005,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2784,2823.60105414859,2863.2021082971796,2902.803162445769,2942.404216594359,2982.0052707429486,3021.6063248915384,3061.2073790401278,3100.8084331887176,3140.4094873373074,3180.010541485897,3219.6115956344865,3259.2126497830764,{"y":3298.813703931666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2784,2732.463221826923,2680.926443653846,2629.3896654807695,2577.8528873076925,2526.3161091346155,2474.7793309615386,2423.2425527884616,2371.7057746153846,2320.1689964423076,2268.632218269231,2217.095440096154,2165.558661923077,{"y":2114.02188375,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":955.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":955.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1810,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1810,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2590,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2784,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2784,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3,636Average Price Target$3,299Lowest Price Target$2,114
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:GH
Eve Burstein
Bernstein
Bernstein
$3,382.44→$3,551.56
Buy
27.57%
Upside
Reiterated
09/09/26
Bernstein Reaffirms Their Buy Rating on Guardant Health (GH)
William Blair Analyst forecast on MX:GH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Guardant Health: FDA Companion Dx Approval for Camizestrant Validates Longitudinal Liquid Biopsy and Supports Buy Rating
Rothschild & Co Redburn Analyst forecast on MX:GH
Jamie Clark
Rothschild & Co Redburn
Rothschild & Co Redburn
$3,433.17
Buy
23.32%
Upside
Initiated
09/08/26
Guardant Health initiated with a Buy at Rothschild & Co RedburnGuardant Health initiated with a Buy at Rothschild & Co Redburn
Goldman Sachs Analyst forecast on MX:GH
Evie Koslosky
Goldman Sachs
Goldman Sachs
$3,551.56
Buy
27.57%
Upside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Guardant Health (NASDAQ: GH) and Neurocrine (NASDAQ: NBIX)
BTIG Analyst forecast on MX:GH
Mark Massaro
BTIG
BTIG
$3,297.87
Buy
18.46%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), NRX Pharmaceuticals (NASDAQ: NRXP) and Innate Pharma (NASDAQ: IPHA)
Piper Sandler Analyst forecast on MX:GH
David Westenberg
Piper Sandler
Piper Sandler
$3,264.05
Buy
17.24%
Upside
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)
Mizuho Securities Analyst forecast on MX:GH
Bradley Bowers
Mizuho Securities
Mizuho Securities
$3,382.44
Buy
21.50%
Upside
Reiterated
08/04/26
Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)
Morgan Stanley Analyst forecast on MX:GH
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$2,959.63→$3,128.75
Buy
12.38%
Upside
Assigned
08/04/26
Guardant Health price target raised to $185 from $175 at Morgan StanleyGuardant Health price target raised to $185 from $175 at Morgan Stanley
J.P. Morgan Analyst forecast on MX:GH
Casey Woodring
J.P. Morgan
J.P. Morgan
$3,297.87
Buy
18.46%
Upside
Reiterated
08/04/26
J.P. Morgan Sticks to Its Buy Rating for Guardant Health (GH)
Stephens Analyst forecast on MX:GH
Mason Carrico
Stephens
Stephens
$3,297.87
Buy
18.46%
Upside
Reiterated
08/04/26
Stephens Remains a Buy on Guardant Health (GH)
Stifel Nicolaus Analyst forecast on MX:GH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$2,198.58→$3,044.19
Buy
9.35%
Upside
Reiterated
08/03/26
Guardant Health price target raised to $180 from $130 at StifelGuardant Health price target raised to $180 from $130 at Stifel
Canaccord Genuity Analyst forecast on MX:GH
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$3,467
Buy
24.53%
Upside
Reiterated
08/02/26
Guardant Health: Buy Rating Reiterated as Strong Q2 Results, Raised 2026 Outlook Support Unchanged $205 Price Target
Guggenheim Analyst forecast on MX:GH
Subbu Nambi
Guggenheim
Guggenheim
$3,213.31
Buy
15.42%
Upside
Reiterated
07/31/26
Analysts Conflicted on These Healthcare Names: Guardant Health (NASDAQ: GH) and Cardinal Health (NYSE: CAH)
TD Cowen Analyst forecast on MX:GH
Daniel Brennan
TD Cowen
TD Cowen
$3,382.44→$3,551.56
Buy
27.57%
Upside
Assigned
07/31/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Regeneron (REGN)
RBC Capital Analyst forecast on MX:GH
Dan Leonard
RBC Capital
RBC Capital
$3,128.75→$3,382.44
Buy
21.50%
Upside
Assigned
07/31/26
Guardant Health (GH) Receives a Buy from RBC Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:GH
Eve Burstein
Bernstein
Bernstein
$3,382.44→$3,551.56
Buy
27.57%
Upside
Reiterated
09/09/26
Bernstein Reaffirms Their Buy Rating on Guardant Health (GH)
William Blair Analyst forecast on MX:GH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Guardant Health: FDA Companion Dx Approval for Camizestrant Validates Longitudinal Liquid Biopsy and Supports Buy Rating
Rothschild & Co Redburn Analyst forecast on MX:GH
Jamie Clark
Rothschild & Co Redburn
Rothschild & Co Redburn
$3,433.17
Buy
23.32%
Upside
Initiated
09/08/26
Guardant Health initiated with a Buy at Rothschild & Co RedburnGuardant Health initiated with a Buy at Rothschild & Co Redburn
Goldman Sachs Analyst forecast on MX:GH
Evie Koslosky
Goldman Sachs
Goldman Sachs
$3,551.56
Buy
27.57%
Upside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Guardant Health (NASDAQ: GH) and Neurocrine (NASDAQ: NBIX)
BTIG Analyst forecast on MX:GH
Mark Massaro
BTIG
BTIG
$3,297.87
Buy
18.46%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), NRX Pharmaceuticals (NASDAQ: NRXP) and Innate Pharma (NASDAQ: IPHA)
Piper Sandler Analyst forecast on MX:GH
David Westenberg
Piper Sandler
Piper Sandler
$3,264.05
Buy
17.24%
Upside
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)
Mizuho Securities Analyst forecast on MX:GH
Bradley Bowers
Mizuho Securities
Mizuho Securities
$3,382.44
Buy
21.50%
Upside
Reiterated
08/04/26
Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)
Morgan Stanley Analyst forecast on MX:GH
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$2,959.63→$3,128.75
Buy
12.38%
Upside
Assigned
08/04/26
Guardant Health price target raised to $185 from $175 at Morgan StanleyGuardant Health price target raised to $185 from $175 at Morgan Stanley
J.P. Morgan Analyst forecast on MX:GH
Casey Woodring
J.P. Morgan
J.P. Morgan
$3,297.87
Buy
18.46%
Upside
Reiterated
08/04/26
J.P. Morgan Sticks to Its Buy Rating for Guardant Health (GH)
Stephens Analyst forecast on MX:GH
Mason Carrico
Stephens
Stephens
$3,297.87
Buy
18.46%
Upside
Reiterated
08/04/26
Stephens Remains a Buy on Guardant Health (GH)
Stifel Nicolaus Analyst forecast on MX:GH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$2,198.58→$3,044.19
Buy
9.35%
Upside
Reiterated
08/03/26
Guardant Health price target raised to $180 from $130 at StifelGuardant Health price target raised to $180 from $130 at Stifel
Canaccord Genuity Analyst forecast on MX:GH
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$3,467
Buy
24.53%
Upside
Reiterated
08/02/26
Guardant Health: Buy Rating Reiterated as Strong Q2 Results, Raised 2026 Outlook Support Unchanged $205 Price Target
Guggenheim Analyst forecast on MX:GH
Subbu Nambi
Guggenheim
Guggenheim
$3,213.31
Buy
15.42%
Upside
Reiterated
07/31/26
Analysts Conflicted on These Healthcare Names: Guardant Health (NASDAQ: GH) and Cardinal Health (NYSE: CAH)
TD Cowen Analyst forecast on MX:GH
Daniel Brennan
TD Cowen
TD Cowen
$3,382.44→$3,551.56
Buy
27.57%
Upside
Assigned
07/31/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Regeneron (REGN)
RBC Capital Analyst forecast on MX:GH
Dan Leonard
RBC Capital
RBC Capital
$3,128.75→$3,382.44
Buy
21.50%
Upside
Assigned
07/31/26
Guardant Health (GH) Receives a Buy from RBC Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
SNDXSyndax Pharmaceuticals
PTGXProtagonist Therapeutics
ONCBeOne Medicines
HITIHigh Tide
IRTCIrhythm Technologies
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

3 Months
William BonelloCraig-Hallum
Success Rate
10/14 ratings generated profit
71%
Average Return
+40.11%
Copying William Bonello's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +40.11% per trade.
1 Year
William BonelloCraig-Hallum
Success Rate
14/14 ratings generated profit
100%
Average Return
+144.95%
Copying William Bonello's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +144.95% per trade.
2 Years
William BonelloCraig-Hallum
Success Rate
14/14 ratings generated profit
100%
Average Return
+296.66%
Copying William Bonello's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +296.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GH Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
7
7
1
0
0
Buy
32
40
64
50
47
Hold
2
2
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
41
49
66
50
47
In the current month, GH has received 47 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GH average Analyst price target in the past 3 months is 3,298.81.
Each month's total comprises the sum of three months' worth of ratings.

GH Financial Forecast

GH Earnings Forecast

Next quarter’s earnings estimate for GH is -$12.75 with a range of -$15.56 to -$10.82. The previous quarter’s EPS was -$15.22. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s earnings estimate for GH is -$12.75 with a range of -$15.56 to -$10.82. The previous quarter’s EPS was -$15.22. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Sales Forecast

Next quarter’s sales forecast for GH is $5.93B with a range of $5.82B to $6.07B. The previous quarter’s sales results were $5.67B. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s sales forecast for GH is $5.93B with a range of $5.82B to $6.07B. The previous quarter’s sales results were $5.67B. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Stock Forecast FAQ

What is MX:GH’s average 12-month price target, according to analysts?
Based on analyst ratings, Guardant Health’s 12-month average price target is 3,298.81.
    What is MX:GH’s upside potential, based on the analysts’ average price target?
    Guardant Health has 18.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Guardant Health a Buy, Sell or Hold?
          Guardant Health has a consensus rating of Strong Buy, which is based on 20 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Guardant Health’s share price target?
            The average share price target for Guardant Health is 3,298.81. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $3,636.12 ,and the lowest forecast is $2,114.02. The average share price target represents 18.49% Increase from the current price of $2,784.
              What do analysts say about Guardant Health?
              Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of Guardant Health?
                To buy shares of MX:GH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.